AIM To investigate the application of Qishen Yiqi dropping pills in patients with coronary heart disease (CHD) after percutaneous coronary intervention (PCI), and its influence on cardiac functions, physical activity and the incidence of major adverse cardiovascular events (MACE).
METHODS A total of 84 patients with CHD treated by PCI in Minda Hospital Affiliated to Hubei University for Nationalities were selected between October 2019 and November 2020. Using random number table method, the patients were divided into control group and study group, with 42 patients in each group. The control group was treated with conventional western medicines and the study group was treated with Qishen Yiqi dropping pills based on the treatment of control group. Clinical effects, cardiac functions, TCM syndrome scores, 6-min walking distance, physical activity level and the occurrence of MACE were compared between the two groups.
RESULTS The total effective rate of clinical treatment in the study group was 92.86%, higher than 76.19% in the control group (P<0.05). After treatment, stroke volume, left ventricular ejection fraction, left ventricular end-systolic diameter, left ventricular end-diastolic diameter, TCM syndrome scores and 6-min walking distance in the study group were better than those in the control group (P<0.01). After treatment, the proportions of patients with high-level and medium-level physical activities in the study group were higher than those in the control group (P<0.05). The incidence of MACE in the study group was 9.52%, significantly lower than 28.57% in the control group (P<0.05).
CONCLUSION Qishen Yiqi dropping pills increase the stroke volume and ejection fraction, improve cardiac functions, promote physical activity and reduce the incidence of MACE in CHD patients after PCI, which are conducive to the patients’ recovery.
DownLoad: